06 April 2021
TruSpine Technologies plc, (AQSE: TSP) the medical device company focused in the spinal (vertebral) stabilisation market, announces that, further to the announcement on 1 March 2021 and disclosure made in the Company's admission document, Evrensel Capital Partners Limited ("Evrensel"), an entity that committed to subscribe on 11 September 2020 for 694,444 new ordinary shares in the Company at a price of 36p per shares, raising gross proceeds of £250,000, has not provided funds due to the Company and is therefore in default on its commitment.
The Company has passed the matter on to its legal advisers.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Truspine Technologies Plc
Tel: +44 (0)20 3638 5025
Ian Roberts, CEO
Cairn Financial Advisers LLP (AQSE Corporate Adviser)
Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
WH Ireland (Broker)
Tel: +44 (0)20 7220 1666
Walbrook PR (Financial PR & IR)
Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiﬁed by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reﬂect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.